Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer’s heart failure drug Inspra accepted in Wales

Pfizer’s heart failure drug Inspra accepted in Wales

24th January 2013

Pfizer's chronic heart failure drug Inspra is to be made available to Welsh NHS patients following a new regulatory ruling.

The All Wales Medicines Strategy Group (AWMSG) has accepted the therapy for use among adult patients in combination with standard optimal therapy, based on evidence showing its effectiveness in reducing the risk of hospitalisation and death.

This decision brings the AWMSG's guidance in line with advice from cardiovascular disease experts at the European Society of Cardiology and fellow UK regulator the Scottish Medicines Consortium.

Cardiovascular disease is Wales' biggest killer, with around one in 100 members of the population suffering from chronic heart failure.

Julian Halcox, professor of cardiology at the Cardiff University School of Medicine, said: "The inclusion of eplerenone into the AWMSG guidelines is good news for patients as ensuring those with heart failure receive the most effective treatments can have a real impact on outcome."

This comes after Pfizer received a European regulatory recommendation for approval of its investigational leukaemia therapy bosutinib earlier this month.ADNFCR-8000103-ID-801527806-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.